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Abbreviations 
AML Acute Myeloid Leukemia 
AUC  Area Under The Curve 
Cmax Maximum (Peak) Serum Concentration 
Cmin Minimum Serum Concentration 
eGFR Estimated Growth Factor Receptor 
EMA European Medicines Agency 
GVHD Graft Versus Host Disease 
HSCT Hematopoietic-Stem-Cell-Transplant  
IFI Invasive Fungal Infection 
MDS Myelodysplastic Syndromes 
MIC Minimum Inhibitory Concentration 
OPC Oropharyngeal Candidiasis 
P-gp P-Glycoprotein 
t1/2 Half-life 
TDM Therapeutic Drug Monitoring 
Tmax Time To Maximum Concentration 
UDP Uridine Disphosphate-Glucuronosyltransferase 
 SUMMARY 
Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of 
invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. 
There is evidence of efficacy in the treatment and prevention of rarer, more difficult-to-treat 
fungal infections. Posaconazole oral suspension solution has shown limitations with respect to 
fasting state absorption, elevated gastrointestinal pH and increased motility. The newly approved 
delayed-release oral tablet and intravenous solution formulations provide an attractive treatment 
option by reducing interpatient variability and providing flexibility in critically ill patients. On 
the basis of clinical experience and furthering clinical studies, posaconazole is a valuable 
pharmaceutical agent for the treatment of life-threatening fungal infections. This review will 
examine the development history of posaconazole and to highlight the most recent advances. 
INTRODUCTION 
Invasive fungal infections (IFIs) are problematic for critically ill patients, with increased risks of 
morbidity and mortality. Prophylactic treatment is often advantageous, as delayed antifungal 
treatment has been shown to increase mortality rates [1,2]. The Infectious Disease Society of 
America guidelines for the use of antimicrobial agents in neutropenic patients with cancer 
suggest antifungal prophylaxis be employed in high-risk patients, including hematopoietic stem-
cell transplantation (HSCT) recipients or intensive chemotherapy for leukemia [3]. 
Unfortunately, safety and tolerability concerns often reduce the utility of antifungals in the clinic. 
The currently available systemic triazoles are divided into two groups: the first generation 
(fluconazole and itraconazole) and the second generation (voriconazole,posaconazole, and 
isavuconazonium) (Figure 1). While these agents all possess the same mechanism of action, each 
has differing anti-fungal activity, efficacy, pharmacokinetics and safety profiles, leading to 
unique therapeutic niches [4,5].  
Posaconazole is a triazole antifungal that boasts an extended-spectrum of activity for prophylaxis 
and treatment for IFIs. Posaconazole has demonstrated efficacy as an antifungal prophylactic in 
HSCT recipients with graft vs. host disease and in neutropenic patients with hematologic 
malignancy. In addition, posaconazole has been an effective salvage therapy option for patients 
that are nonresponsive to standard antifungal therapies [6], Overall, posaconazole covers a wide 
array of IFIs; including, aspergillosis, candidiasis, fusariosis, mucormycosis, cryptococcosis, 
chromoblastomycosis, mycetoma and coccidioidomycosis [7]. Compared to the other azoles 
(fluconazole, itraconazole, and voriconazole), posaconazole has a more favorable safety profile 
[8]. Furthermore, posaconazole activity extends beyond that of other azoles, including 
voriconazole, for instance, which does not cover mucormycosis [9,10].  
CHEMICAL DEVELOPMENT  
Posaconazole is designated chemically as 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-
5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-
ethyl-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one. Its empirical formula is 
C37H42F2N8O4 with a molecular weight of 700.8. It is synthesized solely as the (R,R,S,S) 
enantiomer via a three-step synthesis followed by a micronization step to enhance the dissolution 
rate. Posaconazole is a structurally comparable to itraconazole (Figure 1). Modifications, 
including fluorine in place of chlorine and a furan ring in place of the dioxolane ring, result in an 
extended spectrum of antifungal activity [7].  
PHARMACOLOGY  
Posaconazole, in addition to other triazoles, block ergosterol synthesis through 14 α-demethylase 
(CYP51) inhibition. Ergosterol depletion prevents proper fungal cell wall construction and, cause 
the accumulation of methylated sterol precursorsleading to cell death [11]. Posaconazole 
undergoes negligible oxidative phase 1 metabolism (<2%); its metabolism is facilitated instead 
through a phase 2 biotransformation via uridine disphosphate-glucuronosyltransferase (UDP) 
enzyme pathway. No relevant active metabolites have been identified for posaconazole [12]. 
Posaconazole is both a substrate and inhibitor of the p-glycoprotein (p-gp) efflux transporter 
[13].   
The Biopharmaceutics Classification System (BCS) of the U.S. Food and Drug Administration 
Center for Drug Evaluation and Research lists posaconazole as a Class II compound, indicating 
that it is well absorbed but dissolves slowly (high permeability/low solubility) [14]. The apparent 
volume of distribution of posaconazole ranges from 5 to 25 L/kg, indicating extensive 
distribution and tissue penetration [7]. Posaconazole is highly protein bound (>98%), 
predominately to albumin in a concentration-dependent fashion.  
Posaconaozole is predominately eliminated in the feces (77% of the radiolabeled dose), primarily 
eliminated as parent drug (66% of the radiolabeled dose) in healthy volunteers [15]. 14% of the 
radiolabeled dose is excreted in urine, primarily in the form of glucuronide conjugates. The mean 
half-life (t1/2) of posaconazole ranges from 25-35 hours [16]. 
Posaconazole has shown in vitro activity against a wide variety of fungal pathogens including 
Aspergillus spp., Candida spp., Coccidiodes immitis and Fonsecaea pedrosoi. In addition, some 
species of Fusarium, Rhizopus and Mucor are sensitive to posaconazole [17]. Clinical 
Aspergillus fumigatus isolates have been identified that demonstrate resistance to posaconazole, 
specifically those that harbor CYP51 mutations [18]. 
There are no established pharmacokinetic guidelines with respect to plasma posaconazole for 
breakthrough IFIs [19]. A posaconazole concentration target greater than 0.5 mg/L is 
recommended for prophylactic treatment, with others suggesting a concentration target greater 
than 0.70 mg/L. Cardiothoracic transplant patients possessing posaconazole levels consistently 
exceeding 0.50 mg/L had therapeutically successful outcomes [20]. One report suggests that 
values exceeding 0.70 mg/L do not provide any further reduction in the clinical failure rate, as 
demonstrated in two randomized, active-controlled clinical studies employing posaconazole oral 
suspension [21].  
Oral Suspension Formulation 
The posaconazole oral suspension solution has been reviewed extensively [7,22]; its use has been 
eclipsed by the newer formulations. Briefly, there are several challenges with respect to the 
posaconazole oral suspension formulation. One, this formulation is limited by saturable 
absorption. In a clinical study utilizing healthy men, posaconazole oral suspension given 400 mg 
every 12 hours or 200 mg every 6 hours resulted in a 98% and 220% increase in bioavailability, 
respectively, compared to 800 mg given as a single dose [23]. Secondly, there is also significant 
pharmacokinetic variability in regards to nutrition, as bioavailability increases at a low gastric 
pH along with high-fat meals. [24,25]. Acidic carbonated beverages have been shown to increase 
the bioavailability of posaconazole oral suspension [26]. 
Delayed-Release Oral Tablet Formulation 
The FDA approved a delayed-release oral posaconazole tablet in November 2013. This tablet 
was largely designed to overcome the absorption limitations associated with the oral suspension 
as seen in the clinic and in previous studies. The current posaconazole delayed-release tablet is 
designed to reduce active drug release at low gastric pH, while increasing release at the elevated 
pH of the intestine with an absolute bioavailability of 54% for the oral delayed-release tablet. It 
is suggested that the oral delayed-release tablet be taken with food, though it is not known if the 
oral bioavailability of the tablet improves under fed conditions [16].  
A single- and multiple-dose study was performed in healthy subjects to ascertain optimal dosing 
and to assess pharmacokinetics of this posaconazole tablet formulation [27,28]. During the single 
100 mg dose study, the delayed-release tablet formulation had a higher maximum (peak) serum 
concentration (Cmax) compared to the oral suspension solution in the fasted state (0.39 mg/L vs. 
0.08 mg/L, respectively). In the fed state, the delayed-release tablet formulation still maintained 
a higher Cmax compared to the oral suspension formulation (0.33 mg/L vs. 0.24 mg/L, 
respectively). For the multi-dose study, subjects were randomized to one of two cohorts. Cohort 
1 consisted of either placebo or posaconazole 200 mg SD on day one, a 5-day washout period, 
and then 200 mg BID on day 6, 200 mg QD on days 7-14, and 200 mg BID on days 15-22. 
Cohort 2 received 400 mg, as opposed to 200 mg, and had the same schedule as cohort 1 until 
day 14. Median time to maximum concentration (Tmax) was 4 hours for the 200 mg dose and 5 
hours for the 400 mg dose, while mean t1/2 following was similar for both doses (25 and 26 hours 
for the 200 mg and 400 mg dose, respectively). With the 400 mg dose, the delayed-release tablet 
exhibited linear pharmacokinetics and steady-state concentrations were achieved after 7 days. 
Greater inter-subject variability was noted in exposure values for the 400 mg dose compared to 
the 200 mg dose (54% vs. 32%, respectively). 
A phase 1b, multicenter dose-determining trial was conducted in order to examine the 
pharmacokinetics of posaconazole tablets in patients with acute myeloid leukemia or 
myelodysplasia [29]. The two cohorts were administered posaconazole tablets, 200 mg or 300 
mg daily. The 300 mg cohort reached the predefined steady-state concentration goal of 0.50 and 
2.50 mg/L in 97% of patients, while 79% of patients reached the goal in the 200 mg cohort.  
A phase 3, multicenter trial utilized the 300 mg delayed-release posaconazole oral tablet to 
further examine the pharmacokinetics in acute myeloid leukemia or myelodysplasia patients 
along with recent HSCT recipients [30]. During the 28-day trial period, the predefined steady-
state concentration goal, set at 0.50 – 3.75 mg/L, was achieved in 96% of patients, with 81% 
falling in the range between 0.50 and 2.50 mg/L. These concentration goals are in line with 
targeted recommendations for breakthrough IFIs.   
Intravenous Formulation 
An intravenous posaconazole formulation developed as an aqueous solution containing the 
solubilizer sulfobutyl ether beta-cyclodextrin has also been approved for marketing in the United 
States [31]. Initially, a single-center, two-part rising single- and multiple-dose study in healthy 
adults was performed to evaluate the pharmacokinetics and safety of intravenous posaconazole 
[32]. For the first part of the study, six cohorts covered a single dose posaconazole range from 50 
to 300 mg by 30-min peripheral infusion. Intravenous posaconazole showed a greater-than-dose-
proportional increase in exposure, whereby Cmax values ranged from 0.31 mg/L to 2.84 mg/L for 
the 50 and 300 mg single dose administration, respectively. Part 2 was terminated early due to 
unacceptable rates of infusion site reactions.   
To expand the pharmacokinetic and safety profile of intravenous posaconazole, a two-part study 
was performed, one part classified as phase 1b and the other as phase 3 in order to bridge the 
new posaconazole intravenous solution to the previously approved posaconazole suspension 
[31]. The primary purpose of the phase 1b trial was to identify the posaconazole dose that would 
attain an exposure target of 0.50-2.50 mg/L. A single-dose and two multiple-dose cohorts were 
established for the study, with the multiple dose cohorts used to evaluate the 200 mg or 300 mg 
once daily dose after a twice-daily loading dose on the first day. Subjects attaining steady-state 
exposure goals were 94% and 95% for the 200 mg and 300 mg dosing cohorts, respectively. 
Mean concentration average was 1.19 mg/L and 1.43 mg/L for the 200 mg and 300 mg dosing 
cohorts on day 14, respectively. Intravenous posaconazole demonstrated a similar safety profile 
to the oral suspension formulation. A 300 mg QD dose was recommended for the phase 3 study. 
The pharmacokinetics and safety of the posaconazole intravenous formulations have also been 
investigated [33]. Patients with acute myeloid leukemia, myelodysplastic syndrome, or HSCT 
were enrolled into a study further examining posaconazole intravenous formulation [34]. 
Posaconazole was intravenously administered 300 mg twice daily on day 1 and 300 mg once 
daily for 4-13 days afterwards. Then, they were switched to posaconazole oral suspension 600 
mg or 800 mg in divided doses for up to 23 days for a total treatment period of 28 days. The 
intravenous formulation resulted in higher trough concentrations of posaconazole than either of 
the dosages of oral suspension. Thus, this result shows that the posaconazole intravenous 
solution can be dosed at a level to reach satisfactory exposure for the treatment or prophylaxis of 
fungal infections. 
SAFETY AND TOLERABILITY 
In general, posaconazole has a very good safety and tolerability profile [35,36]. Courtney and 
colleagues demonstrated the tolerability of oral suspension posaconazole in doses up to 400 mg 
twice daily in a Phase I study in healthy subjects [37]. Adverse effects were mild, such as fatigue 
and dry mouth. In the later phase clinical trials, posaconazole was also particularly well 
tolerated. The main side effects experienced by the participants were gastrointestinal distress 
(nausea, vomiting, and diarrhea), neutropenia and elevated liver enzymes [34,38,39]. Patients 
suffering from mucositis, diarrhea, or are in the early post-transplant period in hematopoietic 
stem cell transplant therapy have reduced posaconazole levels when administered the oral 
suspension solution [19]. Overall, posaconazole has favorable safety profile compared to other 
currently approved systemic triazole antifungals (Table 2) [8]. 
Other than infusion site reactions, the intravenous formulation of posaconazole had few 
additional adverse effects. Infusion site reactions, specifically thrombophlebitis, were clinically 
acceptable at 30 minutes compared to 90 minutes for single-dose peripheral administration [32]. 
However, a decrease in infusion time from 90 minutes to 30 minutes did not reduce infusion site 
reactions for multiple-dose administrations. It is recommended that infusion be performed by 
central line when multiple-dose posaconazole administration is necessary.  
Early pooled analysis of 18 controlled studies in healthy volunteers and patients receiving 
posaconazole oral suspension solution indicated low potential to prolong the corrected QT (QTc) 
interval, among other side effects [40]. An initial report identified minimal safety concerns 
regarding elevated hepatic function tests and QTc prolongation for the posaconazole delayed-
release oral tablets [29]. However, an additional study has shown that the oral delayed-release 
tablet increases hepatic enzyme levels in addition to prolonging the QTc interval [41]. As such, 
patients need to be monitored of their hepatic enzyme levels and QTc intervals. 
Drug Interactions 
The other triazole antifungals have numerous drug-drug interactions as they inhibit the P-gp 
transporter in addition to CYP P450 enzymes, thus resulting in increased concentration of other 
drugs [42]. However, posaconazole and fluconazole are less potent inhibitors than voriconazole 
and itraconazole. Posaconazole inhibits CYP3A4 and P-gp, whereas other triazoles may also 
affect CYP2C9 and CYP2C19 [22]. This has important implications for therapy selection. In the 
GVHD patient population, immunosuppressive drugs cyclosporine and tacrolimus are commonly 
used; as they are CYP 3A4 substrates, posaconazole will likely increase their plasma 
concentration potentially resulting in toxicity (Figure 2). The co-administration of posaconazole 
with several CYP3A4 substrates is contraindicated, including substrates known to prolong the 
QTc interval (i.e. terfenadine, cisapride), in addition to HMG-CoA reductase inhibitors (i.e. 
statins) and ergot alkaloids [16]. No further induction or inhibition of additional CYP450 
enzymes at therapeutically relevant concentrations has been identified. 
Reduced posaconazole oral suspension exposure is noted with the concurrent use of 
metoclopramide, phenytoin or rifampin, and the H2 ranitidine [19]. Since the posaconazole oral 
suspension formulation is more readily absorbed at a lower pH, proton pump inhibitors and 
cimetidine have been shown to decrease the AUC of posaconazole [7,43]. Other histamine H2 
receptor antagonists and antacids had no effect on the AUC.  
In contrast to the oral suspension formulation, the absorption profile of the delayed-release 
posaconazole tablet is not affected by gastric acidity or motility. To investigate, healthy 
volunteers were randomized to groups to receive a single 400 mg dose of the delayed-release 
posaconazole tablet alone; with metoclopramide to affect gastric motility; or with an antacid 
(aluminum and magnesium hydroxide), ranitidine, or esomeprazole to affect gastric acidity in a 
crossover trial. [44]. Exposure, Tmax and t1/2 were comparable whether posaconazole was 
administered alone or in combination with medications that affect gastric pH and motility. Future 
studies demonstrated increased plasma concentrations associated with the delayed-release oral 
tablet, as leukemia patients transitioned from posaconazole oral suspension to tablets had 
significantly higher posaconazole concentrations (median, suspension 0.75 mg/L; tablet 1.91 
mg/L without clinically relevant hepatotoxicity [45].  
Use in special populations 
Posaconazole pharmacokinetics are comparable regardless of gender and are not significantly 
affected by ethnicity [16]. Furthermore, posaconazole pharmacokinetics do not differ 
significantly with age. Posaconazole is designated pregnancy category C, such that no adequate 
clinical studies have examined this population [16]. Posaconazole administration has led to 
skeletal malformations in rats at relative concentrations lower than human therapeutic dosing. 
Furthermore, posaconazole administration produced higher rates of bone resorption to occur in 
rabbits, with higher dosages causing a reduction in body weight gain and a reduction in liter size 
in females. Preclinical animal models also suggest that posaconazole may excrete into breast 
milk of lactating females. Prophylaxis studies indicate that mean steady-state posaconazole 
average concentration is consistent in the pediatric population with that of adults [16].  
For prophylaxis of candidiasis, posaconazole has been indicated in several clinical contexts in 
pediatric patients [46]. For allogenic HSCT, posaconazole oral suspension (200 mg TID) is 
recommended for patients greater than grade II GVHD that are at least 13 years of age.  
Posaconazole oral suspension (200 mg TID) is recommended for AML and recurrent leukemia 
patients ages 13 and older after the last dose of chemotherapy until neutrophil recovery. 
Delayed-release posaconazole tablets are now indicated for patients 13 years or older. However, 
the use of posaconazole intravenous injection is not recommended for patients under the age of 
18 due to preclinical safety concerns [16]. 
No posaconazole pharmacokinetic effects have been seen in patients administered 400 mg 
single-dose posaconazole oral suspension with mild to moderate renal impairment; thus, no 
further dose adjustment requirements are recommended for patients with mild-to-moderate renal 
impairment [16]. However, close monitoring for breakthrough IFI is recommended for patients 
with severe renal impairment (eGFR: <20 mL/min). Similar studies have not been conducted 
with the oral delayed-release posaconazole tablets; however, no dose adjustments are 
recommended for mild-to-moderate renal impairment. Posaconazole intravenous injection should 
be avoided in patients with moderate or severe renal impairment as excess accumulation of the 
intravenous vehicle, sulfobutylether-β-cyclodextrin, may be problematic. Accordingly, the serum 
creatinine levels of these patients should be closely monitored [16]. 
No posaconazole oral suspension dose adjustments are recommended for patients with mild to 
severe hepatic impairment [16]. Mean AUC values of a single dose of 400 mg posaconazole oral 
suspension range from 21-43% higher for patients with hepatic impairments. Respective Cmax 
and t1/2 values for patients with hepatic impairments vary compared to normal individuals.  
Similar studies have not been performed with the oral delayed-release tablets or intravenous 
injection; however, no dose adjustments are recommended for either of these formulations with 
patients with mild to severe hepatic impairment [16].  
Immunosuppressant drugs, specifically cyclosporine and tacrolimus, need to have levels 
monitored when given in combination with posaconazole [47]. While concurrent use of 
posaconazole and sirolimus is contraindicated by the manufacturer, a recent study has shown that 
posaconazole can be given in combination with sirolimus in a liver solid organ transplant patient. 
[48]. It is imperative that sirolimus concentration levels are monitored when given in conjunction 
with posaconazole. 
CLINICAL EFFICACY STUDIES 
Phase 2 Clinical Studies 
Two main Phase 2 trials were completed in the clinical development program of posaconazole. 
For the indication of IFI prophylaxis, study P018893 was designed to establish the dose by 
comparing the pharmacokinetic and study P01893 examined pharmacodynamic properties of 
different posaconazole dosing strategies [16,49,50]. This study focused on the treatment of 
patients with azole-refractory IFIs or patients experiencing febrile neutropenia and requiring 
empiric antifungal therapy. 98 patients were randomized to receive posaconazole as an oral 
suspension between 800 mg and 1600 mg every day divided into different dosing schedules. 
Patients continued to receive the drug for a maximum of 6 months or until febrile neutropenia 
resolved. Posaconazole was well tolerated and was comparably effective at all dosing schedules 
in the treatment of the fungal infections. These results agreed with previous pharmacokinetic 
data suggesting that the absorption of posaconazole is saturable and therefore limited. Beyond a 
certain threshold, increasing the dose does not affect posaconazole exposure preventing 
additional therapeutic benefit and worsened adverse effects. 
For the indication of oropharyngeal candidiasis (OPC) treatment, study C/I96-209 was used to 
elucidate the dose while analyzing the pharmacologic profile [16,51]. This trial involved 463 
HIV-infected patients with OPC. The goal of this trial was to compare treatment using various 
doses of posaconazole with an established dose of fluconazole, which is routinely used for this 
indication. Patients were randomized to receive either of the agents with posaconazole at the 
doses of interest and fluconazole at 200 mg once followed by 100 mg daily. Treatment was 
continued for a total of 14 days. Posaconazole was well tolerated and showed similarly efficacy 
at the dose levels and compared to fluconazole. Based on the data, the posaconazole 100 mg 
once daily dose was selected.  
Phase 3 Clinical Studies 
IFI Prophylaxis 
The approval of posaconazole by the FDA was based on four pivotal clinical trials, two for each 
indication – IFI prophylaxis and OPC treatment. Ullmann and colleagues compared the efficacy 
of posaconazole versus fluconazole in preventing IFIs in a multicenter, randomized, double-blind 
trial [39]. 600 patients with HSCT and GVHD or patients who were being treated with highly 
immunosuppressive agents were randomized to receive either agent for 16 weeks. One cohort 
received posaconazole as a 200 mg oral suspension three times daily with placebo capsules once 
daily, while the second cohort received fluconazole as a 400 mg encapsulated tablet once daily 
with placebo oral suspension three times daily. Posaconazole was shown to be non-inferior to 
fluconazole in the prevention of IFIs (5.3% vs 9.0%) and was shown to be superior in the 
treatment of invasive aspergillosis specifically (2.3% vs 7.0%). Between both groups, adverse 
events were similar (36% vs 38%, respectively) as was the rate of discontinuation due to adverse 
events (34% vs 38%, respectively). 
Cornely conducted a study comparing the efficacy of posaconazole to fluconazole and 
itraconazole for IFI prophylaxis in patients treated for cancer who were projected to experience 
neutropenia [52]. 602 patients were randomized and received 200 mg posaconazole three times 
daily as an oral suspension or one of the alternate azoles for up to 12 weeks during their rounds 
of chemotherapy; the choice of the alternate azole (400 mg fluconazole once daily or 
itraconazole 200 mg twice daily) was made by each investigator. Patients were monitored for 
fungal infections by a blinded independent data review committee. Posaconazole was shown to 
be superior in preventing IFIs compared to the alternate azoles (2% vs 8%, respectively). In 
addition, the mean time to IFI was longer with posaconazole (41 days vs 25 days, respectively). 
Lastly, the posaconazole group experienced lower mortality during the treatment period (16% vs 
22%, respectively). Adverse effects were comparable for patients taking each agent.  
OPC Treatment  
The efficacy of posaconazole versus fluconazole for patients with HIV/AIDS in the treatment of 
OPC has been evaluated [53]. 350 patients were randomized and received 200 mg posaconazole 
or fluconazole oral suspension on the first day as the loading dose, followed by 100 mg every 
day of the same drug for a total of 14 days. Blinded evaluators investigated each patient for 
clinical success, which was specified as cure or improvement of OPC. At the end of the trial, 
clinical success was seen in both groups at similar rates (91.7% for posaconazole and 92.5% for 
fluconazole). Of the patients deemed clinically successful 42 days after trial completion, 31.5% 
of the posaconazole patients relapsed compared to 38.2% of the fluconazole patients. Also at the 
42-day follow-up, mycological eradication was greater in patients of the posaconazole arm 
(35.6% vs 24.2%, respectively). Adverse events were comparable in each group. 
In order to investigate the role of posaconazole in azole-refractory OPC, Skriest analyzed 
patients infected with HIV with oropharyngeal or esophageal candidiasis resistant to standard 
azole treatments of fluconazole and itraconazole [38]. Patients received 400 mg twice daily for 3 
days followed by 400 mg daily for 25 days or 400mg twice daily for 28 days. 75% of the 176 
patients experienced clinical success, defined as cure or improvement. Treatment success was 
relatively invariable between the groups taking different regimens. Four weeks after the last 
dose, 74% of 80 patients who had experienced a clinical response had relapsed (80% of patients 
on the daily dosing regimen, 68% of patients on the twice daily dosing regimen). 
Treatment of other Approved Fungal Infections 
Additional studies were conducted in order to support the approval of posaconazole for the 
treatment of a broader range of fungal infections in Europe [17]. 330 patients with varying fungal 
infections, which were resistant to or intolerant of standard therapy including other azoles, 
echinocandins, and amphotericin, were administered posaconazole 200 mg four times daily 
while hospitalized and 400 mg twice daily on an outpatient basis for up to one year. Overall 50% 
of patients responded to posaconazole. The investigators analyzed clinical success rates for each 
fungal infection individually with the following infections showing the best efficacy with 
posaconazole: aspergillosis (42%), fusariosis (39%), chromoblastomycosis or mycetoma (82%), 
coccidioidomycosis (69%). 
Catanzaro and colleagues investigated the role of posaconazole in treating patients with 
coccidioidomycosis [54]. In twenty treatment-naïve patients with nonmeningeal disseminated or 
chronic pulmonary coccidioidomycosis, the study investigators administered 400 mg of 
posaconazole daily. 85% of the patients experienced a response, defined as a 50% or greater 
reduction in the mycoses Study Group score from baseline. Stevens et al. further analyzed the 
use of posaconazole in the treatment of treatment-resistant coccidioidomycosis [55]. Fifteen 
patients with refractory coccidioidomycosis were recruited for this trial. Patients were 
administered 800 mg of posaconazole in divided doses daily for up to a year. At the end of the 
treatment period, 73% of the patients responded to treatment: four showed a complete 
eradication of disease, and seven showed a partial resolution. Posaconazole was well tolerated in 
both trials. 
Off-label Indications 
Posaconazole has also been studied for infections that are rarer, often as salvage therapy in 
smaller, less controlled trials. While clinical experience with posaconazole is limited with these 
indications, there is evidence to support utilization. van Burik and colleagues retrospectively 
analyzed the use of posaconazole in mucormycosis [56]. Information from 91 patients was 
included in this study. Patients were treated with posaconazole; 80% for at least 30 days. 60% of 
patients responded to treatment. Restrepo and colleagues investigated posaconazole’s utility as 
salvage treatment of histoplasmosis [57]. Six patients who had failed other treatments were 
placed on posaconazole 800 mg per day in divided doses. All patients responded to treatment 
within a month as demonstrated by clinical improvement.  
Posaconazole has also demonstrated good activity in the treatment of fungal infection of the 
central nervous system (CNS). Pitisuttithum et al. studied 39 patients with CNS fungal infections 
[58]. Most of these patients had refractory disease (95%) or an HIV infection (74%). The 
infections were caused by a variety of fungi including Cryptococcus, Aspergillus, and a variety 
of rarer fungi (P. boydii C. immitis, H. capsulatum, Ramichloridium mackenziei, Apophysomyces 
elegans, and Basidiomycetes sp.). Patients were administered the posaconazole oral suspension at 
800 mg per day in divided doses for at least a month and up to one year. Clinical responses were 
seen in 48% of the patients infected with Cryptococcus and in 50% of the patients with the other 
fungal infections. This trial provides evidence that posaconazole can be useful as salvage therapy 
for a wider variety of fungal infections and in the CNS. 
Post-marketing Surveillance 
The FDA required pediatric studies to be completed secondary to the approval of posaconazole. 
Completing one study that addressed the use of posaconazole in this population, Döring and 
colleagues compared itraconazole, voriconazole, and posaconazole in pediatric patients with 
allogenic HSCT as an oral antifungal prophylactic agent [59]. 150 patients between the age of 
seven months and 18 years were divided evenly into three cohorts to receive 5 mg/kg twice daily 
itraconazole, 100 mg twice daily (or 200 mg twice daily if body weight >40 kg) voriconazole, or 
200 mg thrice daily posaconazole. Patients also received antiviral and antibacterial prophylaxis 
for other possible infections. At the end of the observation period (maximum of 220 days after 
HSCT), there were no deaths due to IFIs or even any cases of “proven” or “probable” IFIs in the 
patients. There were several “possible” infections: two in the itraconazole group, three in the 
voriconazole group, and none in the posaconazole group. The differences between “proven”, 
“probable”, and “possible” were analyzed secondary to the National Institute of Allergy and 
Infectious Diseases Mycoses Study Group criteria. Ultimately, the three agents were deemed 
non-inferior to each other in terms of efficacy. Comparing the safety profiles, the adverse effect 
ratio was comparable between all three groups, with increased liver enzymes representing one of 
the most common events. 
REGULATORY AFFAIRS 
Posaconazole has been approved to treat fungal infections in the United States and European 
Union with the trade name Noxafil®. Posaconazole is marketed as Posanol in Canada [16]. 
Labeled indications in the US and Europe are listed in Text Boxes 1 and 2. The FDA approved 
posaconazole for prophylaxis of the Aspergillus and Candida IFIs in immunocompromised 
patients of at least 13 years of age in September 2006, and it was approved for the treatment of 
oropharyngeal candidiasis including those cases refractory to other azole antifungals in October 
2006 [60,61]. For both indications, posaconazole was approved as a 40 mg/mL oral suspension. 
Posaconazole was subsequently approved as a delayed-release tablet in addition to an 
intravenous solution for the indication of invasive Aspergillus and Candida infection prophylaxis 
in November 2013 and March 2014, respectively [62,63]. In the United States, posaconazole’s 
patent is scheduled to expire in 2019.  
The European Medicines Agency (EMA) has approved posaconazole as an oral suspension and 
as a gastro-resistant tablet for treatment of a wider variety of IFIs (aspergillosis, fusariosis, 
chromoblastomycosis and mycetoma, coccidioidomycosis, and oropharyngeal candidiasis) 
including those cases refractory to standard antifungal therapy. In addition, posaconazole is 
approved for the prevention of IFIs in patients whom are receiving immunosuppressive therapy 
after receiving HSCT or chemotherapy for acute myelogenous leukemia or any other 
myelodysplastic syndrome [64]. For all of these indications, posaconazole was approved as an 
oral suspension and as a gastro-resistant tablet in October 2005. 
The FDA specified a number of post-marketing commitments from posaconazole. For the IFI 
indication, the FDA required a pediatric study in patients from age zero months to twelve years 
of age based on the Pediatric Research Equity Act (PREA). For the OPC indication, a pediatric 
study is also required but in patients from zero months to sixteen years of age. In addition, the 
FDA requested a study among patients receiving IFI prophylaxis at risk for low absorption in 
order to explore alternate dosing strategies and the utility of therapeutic drug monitoring [60,61]. 
These studies were originally required by 2011. Since then, the FDA has granted a deferral 
extension, and the studies will need to be completed by 2019 with the exception of the study 
involving alternate dosing strategies and TDM. The FDA has released the company from the 
obligation to complete that study [65]. For the new formulations, pediatric studies are also 
required and will need to be completed within the next ten years [62,63]. (Figure 3) 
CONCLUSION 
Posaconazole is a useful antifungal agent. This drug has shown efficacy in the role of IFI 
prophylaxis, the treatment of OPC and salvage treatment for refractory fungal infections. 
Overall, posaconazole has a favorable safety and tolerability profile. However, the initially 
approved oral suspension formulation has a wide interpatient variability with respect to 
absorption. The systemic availability of the oral suspension can be improved through 
administration with a high-fat meal, nutritional supplement or acidic beverage in addition to 
divided daily doses. The suspension has shown a reduction in systemic availability when 
administered with proton-pump inhibitors in addition to pharmacotherapeutics that increase 
gastric motility. Diarrhea and mucositis have both also been shown to reduce the bioavailability 
of posaconazole.  
The administration of multiple daily doses with a full meal or nutritional supplement can be 
difficult for patients whom have difficulties swallowing. As such, the recent approval of a 
delayed-release tablet that requires administration only once daily and does not appear to be 
clinically affected by food, alterations in gastric pH or motility represents a new option for the 
prophylaxis of IFI. As it achieves consistently higher average serum concentrations, the delayed-
release tablet is a better option than suspension for both prophylaxis and treatment of IFI. An 
intravenous formulation has been recently developed and approved, which provides even greater 
access to patient populations.  
FIVE-YEAR VIEW 
Unlike in the United States, posaconazole has not been approved in the European Union as a 
delayed-release tablet or as a solution for intravenous administration. However, Merck has 
received “positive opinions” from the Committee for Medicinal Products for Human Use inside 
the EMA [66,67]. This signifies that European Commission will review the new drug 
formulations further and likely approve it in the near future, following the precedent set by the 
FDA.  
Posaconazole has been increasingly studied for other fungal infections beyond those infections 
for which it was originally approved by the major regulatory bodies. Elewski and colleagues 
investigated posaconazole in the treatment of toenail onychomycosis and showed improved cure 
rates compared to the commonly used antifungal agent terbinafine [68]. Posaconazole has also 
shown some potential for use in Chagas disease and chronic granulomatous disease [69,70], a 
significant finding as both of these conditions currently have limited therapeutic options. With 
further investigation, posaconazole may be readily used for these indications in the future.  
Furthermore, the effect of posaconazole in pediatric patients will become clearer as the PREA-
required studies are completed in the next few years. Favorable outcomes are expected given the 
positive safety data of the posaconazole oral suspension in pediatric patients. Thus, the use of the 
posaconazole formulations will likely increase over time in this subset of patients. 
Therapeutic drug monitoring (TDM) has been increasingly suggested for posaconazole oral 
suspension therapy, as inter-patient concentration variability is high as is the risk for under-
exposure. Prophylactic target posaconazole concentrations range from at least >0.5 mg/L to >0.7 
mg/L. As such, a general consensus has yet to be determined. A recent report from Hoenigl and 
colleagues suggests the need for therapeutic drug monitoring, as personal on-site education of 
low posaconazole plasma concentrations can lead to >40% increase in sufficient plasma 
concentrations [71]. These findings are consistent with a previously reports that found that cases 
of breakthrough infections were all associated with low posaconazole plasma concentrations 
[19,21,72]. Bryant et al. (2011) was one of the first studies to report on therapeutic drug 
monitoring of prophylactic posaconazole in patients with acute myelogenous leukemia or 
myelodysplastic syndrome [73]. In this study, greater than 7% of patients did not reach the lower 
target limit of 0.7 mg/L. Of the 21 patients, three developed ‘proven’ or ‘possible’ fungal 
infections, all three patients having posaconazole concentrations < 0.5 mg/L. Since posaconazole 
is liable to interact with many other pharmaceutical agents, several sources recommend TDM for 
posaconazole during the duration of multimodal therapy. This may be particularly useful in cases 
where posaconazole is used with an agent with whom it has a drug-drug interaction, which is 
common as many agents used for cancer, HIV, and transplants are CYP3A4 substrates, e.g. 
tacrolimus and cyclosporine. With time, a consensus will be reached concerning TDM the 
appropriate concentration goals for effective posaconazole treatment. 
Also on the horizon, isavuconazonium is a novel triazole agent, which has recently been 
approved by the FDA for the treatment of aspergillosis and mucormycosis and is available as its 
prodrug isavuconazonium  [74]. Preliminary data from Phase 3 studies suggests that it may have 
similar efficacy as voriconazole with fewer adverse effects in treating IFIs [75,76]. 
Isavuconazonium had a relatively quick regulatory timeline because the prognosis of 
mucormycosis is so poor at the moment that the FDA labeled isavuconazonium as an orphan 
drug and as a Qualified Infectious Disease Product for expedited review [77]. Following the 
approval of isavuconazonium, it will likely influence both the European and US markets. It will 
present a good option for mucormycosis and may, in fact, be used instead of posaconazole for 
some patients suffering from invasive aspergillosis.  
EXPERT COMMENTARY 
Posaconazole has been recognized by the guidelines for quite a few therapeutic uses beyond its 
FDA approved indications. The Infectious Disease Society of America (IDSA) has included 
them in their guidelines for aspergillosis, cryptococcosis, candidiasis, skin and soft tissue 
infections, and antimicrobial prophylaxis in neutropenia [3-5,78,79]. The IDSA guidelines on 
skin and soft tissue infections specifically recommend posaconazole for the treatment of 
aspergillus, mucormycosis, and fusariosis. Posaconazole is also recommended for the general 
prophylaxis and treatment of IFIs in the respective guidelines for patients affected by HIV, 
hematopoietic cell transplantation, and cancer [80-82] (Figure 5). 
Numerous favorable pharmacoeconomic analyses have been published for posaconazole [83-86]. 
In these studies, the usage of posaconazole was primarily studied for the prevention of IFIs 
secondary to HSCT or secondary to febrile neutropenia in acute myeloid leukemia or 
myelodysplastic syndrome. Lyseng-Williamson (2011) specifically suggested that posaconazole 
was the dominant option compared to standard antifungal therapy in many markets if not simply 
a cost-effective choice [86]. Compared to the other azole antifungals, posaconazole occupies a 
unique place in therapy. It can be used in fungal infections resistant to fluconazole and 
itraconazole. Posaconazole can also be used for prophylaxis of a wider variety of fungal 
infections than voriconazole. As the newest agent in a long-standing class of pharmaceuticals, 
there will be some time before prescribing healthcare providers accumulate enough clinical 
experience with this agent and become accustomed to it. However, the addition of the delayed-
release tablet, and potentially an intravenous formulation, as options will certainly accelerate this 
process as it allows for more convenient dosing.
 KEY ISSUES 
 Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality for 
immunocompromised patients; unfortunately, the clinical usefulness of many antifungal 
agents is limited by safety and tolerability 
 Posaconazole is a relatively safe and well-tolerated broad-spectrum azole antifungal 
agent. 
 Newer posaconazole formulations, oral tablet and intravenous, increase its availability to 
larger patient population. 
 Posaconazole is a cost-effective and dominant option compared to standard antifungal 
therapy in many markets. 
 Posaconazole continues to be studied for additional fungal infections beyond original 
approval, including toenail onychomycosis, Chagas disease and chronic granulomatous 
disease. 
 Success of posaconazole has spurred enhanced development of future azole antifungal 
agents, including isavuconazonium. 
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